Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
Lung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/23/5614 |
| _version_ | 1797507620923244544 |
|---|---|
| author | Chun Ho Szeto Walid Shalata Alexander Yakobson Abed Agbarya |
| author_facet | Chun Ho Szeto Walid Shalata Alexander Yakobson Abed Agbarya |
| author_sort | Chun Ho Szeto |
| collection | DOAJ |
| description | Lung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered as a novel approach to improve survival in patients with early-stage NSCLC. Since immune checkpoint inhibitors have transformed the treatment of advanced NSCLC, there is a growing interest in the role of immunotherapy in early-stage NSCLC. In this review, we summarize reported and ongoing clinical trials of immunotherapy in both neoadjuvant and adjuvant settings. We also highlight unaddressed issues in this field of research, such as the predictive markers, the optimal combination therapy, and the need for adjuvant immunotherapy. More studies are needed to optimize the treatment regimen of immunotherapy in patients with early-stage NSCLC. |
| first_indexed | 2024-03-10T04:51:04Z |
| format | Article |
| id | doaj.art-211c42d8941c4a41879a9654fb5aa29c |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:51:04Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-211c42d8941c4a41879a9654fb5aa29c2023-11-23T02:36:45ZengMDPI AGJournal of Clinical Medicine2077-03832021-11-011023561410.3390/jcm10235614Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and FutureChun Ho Szeto0Walid Shalata1Alexander Yakobson2Abed Agbarya3Medical School for International Health, Ben-Gurion University of the Negev, Beer Sheva 84101, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer Sheva 84105, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer Sheva 84105, IsraelOncology Department, Bnai Zion Medical Centre, Haifa 31048, IsraelLung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered as a novel approach to improve survival in patients with early-stage NSCLC. Since immune checkpoint inhibitors have transformed the treatment of advanced NSCLC, there is a growing interest in the role of immunotherapy in early-stage NSCLC. In this review, we summarize reported and ongoing clinical trials of immunotherapy in both neoadjuvant and adjuvant settings. We also highlight unaddressed issues in this field of research, such as the predictive markers, the optimal combination therapy, and the need for adjuvant immunotherapy. More studies are needed to optimize the treatment regimen of immunotherapy in patients with early-stage NSCLC.https://www.mdpi.com/2077-0383/10/23/5614adjuvantimmune checkpoint inhibitorsimmunotherapyneoadjuvantnon-small-cell lung cancer (NSCLC) |
| spellingShingle | Chun Ho Szeto Walid Shalata Alexander Yakobson Abed Agbarya Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future Journal of Clinical Medicine adjuvant immune checkpoint inhibitors immunotherapy neoadjuvant non-small-cell lung cancer (NSCLC) |
| title | Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future |
| title_full | Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future |
| title_fullStr | Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future |
| title_full_unstemmed | Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future |
| title_short | Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future |
| title_sort | neoadjuvant and adjuvant immunotherapy in early stage non small cell lung cancer past present and future |
| topic | adjuvant immune checkpoint inhibitors immunotherapy neoadjuvant non-small-cell lung cancer (NSCLC) |
| url | https://www.mdpi.com/2077-0383/10/23/5614 |
| work_keys_str_mv | AT chunhoszeto neoadjuvantandadjuvantimmunotherapyinearlystagenonsmallcelllungcancerpastpresentandfuture AT walidshalata neoadjuvantandadjuvantimmunotherapyinearlystagenonsmallcelllungcancerpastpresentandfuture AT alexanderyakobson neoadjuvantandadjuvantimmunotherapyinearlystagenonsmallcelllungcancerpastpresentandfuture AT abedagbarya neoadjuvantandadjuvantimmunotherapyinearlystagenonsmallcelllungcancerpastpresentandfuture |